Stock BIO3 BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biotest AG Deutsche Boerse AG

Equities

BIO3

DE0005227235

Market Closed - Deutsche Boerse AG
Other stock markets
 07:20:01 10/05/2024 BST 		5-day change 1st Jan Change
27.6 EUR +0.36% Intraday chart for Biotest AG -3.83% -10.39%
05-07 Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-19 Biotest Launches New Plasma Collection Center in Germany MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOTEST AG Stock Biotest AG
-10.39% 1.48B -
CSL LIMITED Stock CSL Limited
-2.61% 89.08B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.55% 40.9B
A-
BIOGEN INC. Stock Biogen Inc.
-14.40% 32.25B
B-
UCB Stock UCB
+55.89% 25.14B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.96% 15.39B
C
INCYTE CORPORATION Stock Incyte Corporation
-15.50% 11.91B
B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.29% 11.89B
B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.75% 11.64B
D+
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.87% 9.03B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. BIO3 Stock
  5. Ratings Biotest AG